Abarelix vs Degarelix — Peptide Comparison

Abarelix vs Degarelix — Peptide Comparison Abarelix vs Degarelix — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Abarelix 100 mg–500 mg mg Degarelix 80 mg–240 mg mg Frequency Once daily Administration Intramuscular injection (depot formulation) As directed by healthcare provider Cycle Length Ongoing/indefinite Onset Speed Moderate (1-2 weeks) Evidence Level Strong human trials (Phase 3 or FDA approved) Efficacy Rapid Hormone Control Advanced Cancer Management Patient Tolerability Rapid Testosterone Control Extended Duration Clinical Efficacy Technical Data Molecular Formula C72H95ClN14O14 Molecular Weight 1416.1 g/mol Half-Life Approximately 13 days Bioavailability ~100% (intramuscular depot injection) CAS Number 183552-38-7 C82H103ClN18O16 1632.3 Da ~53 days (median terminal half-life) 100% (subcutaneous injection) 214766-78-6 Protocols standard 100 mg Day 1, 15, 29, then every 4 weeks Up to 12 months (effectiveness beyond 12 months not established) This is the FDA-approved dose for advanced prostate cancer. A 100 mg shot is given into the buttock muscle on day 1, 15, and 29, then once every 4 weeks. The drug was sold as Plenaxis. [4] starting 240 mg (two 120 mg injections) One time (loading dose) Single starting dose FDA-approved loading dose for advanced prostate cancer, given as two separate deep injections under the skin of the belly. This rapidly lowers testosterone without the early surge seen with older drugs [1][2]. 80 mg Every 28 days Ongoing FDA-approved maintenance dose, started 28 days after the loading dose. Keeps testosterone at castrate levels in over 97% of patients [1][2]. Applications Reducing testosterone levels in prostate cancer Abarelix is particularly well-suited for individuals focused on reducing testosterone levels in prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Slowing cancer progression in advanced disease Abarelix is particularly well-suited for individuals focused on slowing cancer progression in advanced disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Managing hormone-dependent cancer symptoms Abarelix is particularly well-suited for individuals focused on managing hormone-dependent cancer symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Men with advanced or metastatic prostate cancer requiring rapid hormone control Degarelix is particularly well-suited for individuals focused on men with advanced or metastatic prostate cancer requiring rapid hormone control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Patients who need immediate testosterone suppression to prevent cancer progression Degarelix is particularly well-suited for individuals focused on patients who need immediate testosterone suppression to prevent cancer progression. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Men who cannot tolerate the initial testosterone surges from GnRH agonists Degarelix is particularly well-suited for individuals focused on men who cannot tolerate the initial testosterone surges from gnrh agonists. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Mild discomfort at treatment site Hot flashes and sweating Decreased libido and sexual dysfunction Increased liver enzymes Injection site reactions (pain, redness, swelling) Abdominal pain and gastrointestinal symptoms Headache and dizziness Weight changes Gynecomastia (breast tissue enlargement) Bone density loss with long-term use Serious Severe allergic reaction Injection site pain (28% of patients) Injection site redness or erythema (17%) Hot flashes (26% experience them) Increased liver enzymes and gamma-glutamyltransferase (10%) Weight gain (9%) Hypertension or elevated blood pressure (6%) Back pain (6%) Chills (5%) Constipation (5%) Urinary tract infection (5%) Injection site swelling (6%) Injection site induration or hardness (4%) Decreased sex drive and erectile dysfunction Gynecomastia (breast tissue growth) Testicular atrophy (shrinking) Research Status FDA Status FDA approved for other use Safety Overview Abarelix carries significant safety concerns primarily related to histamine release reactions, which led to its voluntary withdrawal from the U.S. market in 2006. Serious allergic responses including anaphylaxis, flushing, and hypotension have been documented. Long-term use poses substantial risks of bone density loss, cardiovascular effects from hormonal suppression, and metabolic complications including weight gain and altered lipid profiles. Liver enzyme elevations occur in 5-10% of patients. All use requires intensive medical supervision with regular monitoring of testosterone levels, liver function, bone density, and cardiovascular markers. Contraindications xPregnancy or lactation xSevere hypersensitivity reactions to peptide therapeutics xHistory of anaphylaxis with similar compounds FDA approved for this use Degarelix is an FDA-approved GnRH antagonist with safety data from Phase 3 trials and post-market use in prostate cancer treatment. Advantages over GnRH agonists include absence of testosterone flare, allowing rapid castration without initial symptom surge. Primary safety concerns relate to intentional hormone suppression: hot flashes occur in 40-70% of men, erectile dysfunction in 40-60%, bone density loss of 2-3% annually, and cardiovascular risks in patients >65 years. Injection site reactions (erythema, induration) occur in 20-30% of patients and can be severe in a small percentage. Liver enzyme elevations appear in 5% of patients. QT prolongation potential exists and cardiac monitoring is recommended in susceptible patients. xHistory of severe hypersensitivity to degarelix xAllergy to any product components (mannitol or other additives) xActive untreated severe anaphylaxis risk Decision Guide Choose Abarelix if... Reducing testosterone levels in prostate cancer Slowing cancer progression in advanced disease Managing hormone-dependent cancer symptoms Choose Degarelix if... Men with advanced or metastatic prostate cancer requiring rapid hormone control Patients who need immediate testosterone suppression to prevent cancer progression Men who cannot tolerate the initial testosterone surges from GnRH agonists